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Objectives: The aim of our study was to
report our experience with patients affect-
ed by Erectile Dysfunction (ED) and undergoing penile pros-
thetic implantation (PPI) in a single center by a single sur-
geon.
Material and Methods: We retrospectively evaluated the
clinical outcome of 500 patients (mean age: 51.5 years,
range: 20-86 years) affected by ED and referred to our pri-
vate andrological center from January 1984 to December
2013 who underwent penile prosthesis implantation, includ-
ing the reported level of patient satisfaction. 
Results: 182 silicone, 180 malleable, 18 monocomponent
hydraulic and 120 multicomponents hydraulic prostheses
were implanted by the same experienced surgeon. All
patients were hospitalized for the procedure. All patients
were evaluated immediately, 1 month (496 patients) and, for
the great majority, every year after implantation. One hun-
dred twenty five patients were lost to follow-up. Twenty two
patients underwent revision surgery for complications in the
postoperative period. The most serious postoperative compli-
cations were mechanical problems (45 patients, 9.0%) and
infection (15 patients, 3%). Forty two (8.4%) prostheses
were explanted. Overall, 80% (400/500) of patients were
able to have sexual intercourse and were fully satisfied with
the results.
Conclusions: In our experience prosthetic surgery should be
considered a good solution for men affected by ED and not
responsive to other therapeutic solutions. Prosthetic surgery
can be performed not only in large public hospitals but also
in smaller private facilities.
KEY WORDS: Impotence; Erectile Dysfunction; Penile Disease;
Penile Prosthesis; Impotence Treatment; Impotence Surgery;
Prosthesis Complications; Prosthesis Infections.
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In Italy, the use of MUSE and vacuum pumps never
spread, and penile prosthesis implantation (PPI) did not
develop as in other western countries. 
Our private andrology center has been performing PPI,
carried out by the same experienced surgeon (DP) since
1984. After 30 years of surgical activity we wanted to
review our experience with 500 patients affected by ED
and undergoing PPI. We report the different types of
implanted prostheses, any complication (medical com-
plications, hemorrhages, micturition problems, infec-
tions, mechanical failures during hospitalization and the
postoperative period) and the level of personal and rela-
tional acceptance of this ED treatment.
MATERIALS AND METHODS
From January 1984 to December 2013, 35,675 patients
(5-86 years old, mean age: 48.8) underwent an andro-
logical visit at our andrology center due to routine uro-
andrological screening (1097 pts. 3.0%), bladder and
prostate diseases (4826 pts., 13.5%), genital malforma-
tions (2120 pts., 5.9%), infertility (12.555 pts., 35.2%),
urogenital infections (6400 pts., 17.9%), ejaculatory
(1645 pts., 4.6%) or erectile problems (8032 pts.,
22.5%) (Figure 1).
One specialist (DP) saw all the pts., collected their med-
ical history, performed the clinical examination and
organized the diagnostic protocol, at the end of which an
individualized therapeutic measure was suggested. 
A total of 8032 pts. (22.5%, mean age 48 years, range 18-
86 years) attended the center for problems concerning the
penis and its function. Out of them 436 (6%) did not
return for successive consultations. In total 7564/8032
patients completed the diagnostic program, all undergoing
blood and hormone assays, color duplex ultrasonography
and intracavernous PGE1 test. Furthermore 383 patients
underwent the Rigiscan nocturnal test and, up to 2008,
212 patients underwent dynamic cavernosometry and
cavernosography. Other specific investigations were per-
formed in particular cases.
In 1984, at the beginning of our experience, only psycho-
logical, hormonal and surgical (prostheses) solutions could
be offered to patients with ED. In 1987 we started offering
self-injections of vasoactive drugs (7, 8). Between 1988 and
1998 we performed 86 venous surgical procedures (5, 6).
DOI: 10.4081/aiua.2015.3.216
INTRODUCTION
Over the last century, efforts to treat ED have led to the
development and use of psychological treatment (early
1900s), hormonal therapies (1960) (1, 2), prosthetic sur-
gery (1971) (3, 4), arteriovenous surgery (1981) (5, 6),
vasoactive intracavernosal self-injection (1982) (7, 8),
vacuum pumps (1986) (9), intraurethral PGE1-medicated
urethral system for erections (MUSE) (1994) (10) and 5-
phosphodiesterases inhibitors (5PDHEi) (1997) (11). 
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With the appearance of 5PDEis in 1997 (11), many of our
patients were able to benefit from a simple new treatment.
The vacuum system (9) and MUSE (10) were rarely sug-
gested for the treatment of ED in our patients.
Patients who underwent PPI signed a detailed informed
consent form and agreed to pay the related costs (private
clinic, surgical and anesthesiologist fees, prosthesis, post-
operative follow-up). These medical expenses are not
covered by the Italian National Health Service. This aspect
undoubtedly influenced the choice of many patients as
to whether or not to opt for surgery and if so, what pros-
thesis to implant; many patients could not afford this
option. 
Any aspirin and anticoagulant treatments were stopped
10 days before surgery. In all diabetic patients, blood glu-
cose levels were stabilized before surgery.
RESULTS
Of the 7564 pts with ED, 3010 (39.8%) were diagnosed
with arterial insufficiency, 1339 (17.7%) with Peyronie’s
disease, 1135 (15.0%) with venous insufficiency, 1029
(13.6%) with diabetic neurovascular problems, 393
(5.2%) with hormonal dysfunction, 340 (4.5%) with
post-surgical neurovascular problems, and 318 (4.2%)
with psycho-morphological complaints.
Implantation of a cavernous prosthesis to restore pene-
trative ability was suggested to 610 patients. 500
(81%) patients agreed to the procedure. All
patients in a stable relationship were asked to
inform their partner about their choice. The con-
clusive diagnosis of these 500 patients was: arteri-
al disease in 192 (38.4%), venous disease in 137
(27.4%), Peyronie’s disease in 70 (14.0%), dia-
betes mellitus in 60 (12.0%) and previous pelvic
surgery in 30 (6.0%). 11 (2.2%) patients with no
specific organic disease opted for a prosthetic
implant after psychotherapy (Table 1).
Surgical procedure
Until 2002, patients were admitted to the clinic
the day before operation (332/500, 66%). In the
last 10 years we have preferred, when possible, to
hospitalize patients on the day of surgery
(168/500, 34%). Patients stayed in the clinic for at
least 24 hours. Hospitalization duration ranged
between 1 and 7 days (mean 2.6). 
In the last 13 years we have generally prescribed
oral Ciprofloxacin from 3 days before surgery to 7
days post-surgery, Gentamicin sulfate 80 mg intra-
venously from 1 day before surgery to 1 day post-
surgery and Ceftriaxone 2 g. intravenously just
before surgery and 1 g for 7 days post-surgery.
Patients were recommended to clean their genitals
with Iodopovidone fluid twice a day for the 3 days
leading up to surgery (12). Since 2006, we have per-
formed skin shaving as routinely done for other sur-
gical procedures a few hours before surgery. Usual
Iodopovidone cleansing in the operating table.
In 76 cases (mainly at the beginning of our expe-
rience) we used general anesthesia. Currently,
most procedures are performed under spinal anes-
thesia. In 68 cases of implants of semi-rigid malleable
rods we used local anesthesia with deep sedation. A ure-
thral catheter was inserted in all patients in the operating
room and maintained until the day after surgery. All
penises were carefully dressed until the removal of the
catheter. Urinary retention affected only 13 cases, treated
by re-catheterization for 1-2 days. One patient retained
the catheter for 10 days. The skin incision was infrapu-
bic in 76, subcoronal in 24, subcoronal and penoscrotal
in 12 and penoscrotal in 388 patients.
In 122 patients we found a thick cavernous fibrosis and
used the Carrion-Rossello cavernotome (13) to dilate the
cavernous body to the desired caliber. In 48 cases of
penile curvature, insertion of the rods successfully
No.  patients (%)
Disease 500
Arterial disease 192 (38.4%)
Venous disease 137 (27.4%)
Peyronie’s disease 70 (14%)
Diabetes 60 (12%)
Post pelvic surgery 30 (6%)
Other 11 (2.2%)
Table 1. 
Conclusive diagnosis of the 500 patients 
with penile prostheses.
Figure 2. 
Flow diagram of the study.
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straightened the penis. In a few cases a Wilson maneuver
(14) was used, with satisfactory results. In 8 patients
with a persisting significant curvature after malleable
implant, we performed a plaque incision without any
suture. In 35 cases (both with malleable and hydraulic
implants) we excised the plaque and used various artifi-
cial heterologous patches (SIS, Pelvicol, Veritas, Hydrix)
(15). There were no significant complications associated
with patch insertion.
In the last 10 years, after implanting a hydraulic system
we have used aspirating drainage in the scrotum until 1
day post-surgery (16).
All patients underwent a clinical visit 7-15 days after sur-
gery. All patients returned after 30-40 days for a second
medical visit. Most also returned regularly after 1 year
but 86 (17%) were lost to follow-up after 1 year.
Prosthesis implantation
Overall, we implanted 182 silicone semi-rigid rods (74
Almed Implantal, 34 SSDA-GIS, 30 Eurogest, 25 Small-
Carrion and 19 Subrini) and 180 malleable rods (66
Mentor Acuform-Coloplast Genesis, 54 AMS 600, 25 Jonas-
Jacobi, 14 Vedise, 14 Dacomed Omniphase, 6 Dacomed
Duraphase, 1 AMS Spectra). A total of 138 patients with
sufficient income or supported by private medical insur-
ance opted for a hydraulic prosthesis. We implanted 18
hydraulic monocomponent prostheses (10 AMS
Hydroflex, 8 AMS Dynaflex) and 120 multicomponent
prostheses (38 Mentor Alpha I, 25 AMS 700 CX, 20
Coloplast Titan, 17 Mentor Mark II, 14 AMS 700 Ultrex, 3
AMS 700 LGX, 3 AMS Ambicor) (Table 2).
Complications
Medical complications
We recorded 22 medical complications clearly related to
the surgical procedure.
In two cases (0.4%) we perforated the septum during
cavernous dilation and inserted the two rods in the same
cavernous space. After discovering the problem we re-
inserted the two rods correctly in the cavernous spaces,
with good results and no further complications.
In one case (0.2%) the tip of the cavernous body was
perforated. We detached the glans, applied a patch of
Veritas, and re-implanted a rod 0.5 cm shorter than the
length measured during operation. No subsequent com-
plication was recorded.
In another patient (0.2%) we perforated the crus of one
cavernous body during dilation with the cavernotomes.
We performed a new perineal incision to detect the per-
foration site, which was sutured after placing an RT
extender in the crus of the cavernous body (17). The
insertion of the rod was subsequently successful. 
We did not register any bladder lesion when hydraulic
prostheses were implanted.
Hemorrhage
In 2 (0.4%) cases of semi-rigid prostheses (penoscrotal
incision) we recorded a scrotal hematoma the day after
Age
Prostheses Patients Yrs, range Mean Mechanical Surgical failures Explants complications
500 20-86 51.0 48 (9.6%) 26 (5.2%) 53 (10.6%)
Soft Silicone 182 20-73 39.7 2 (1.2%) 7 (3.8%) 1 (0.6%)
Almed Implantal 74 20-73 36.3 1 3 0
Ssda-Gis 34 22-62 43.3 1 1 0
Eurogest 30 29-65 40.2 0 1 1
Small-Carrion 25 27-73 46.2 0 2 0
Subrini 19 30-38 0 0 0
Semirigid Malleable 180 28-86 53.7 7 (3.8%) 4 (2.2%) 8 (4.4%)
Mentor Acuform-Coloplast Genesis 66 28-83 53.2 0 1 1
Ams 600 54 28-85 53.5 0 2 0
Jonas 25 35-65 45.4 1 0 1
Vedise 14 55-67 50.6 0 0 0
Omniphase 14 44-72 67.4 3 1 3
Duraphase 6 49-86 63 3 0 2
Ams-Spectra 1 51 51 0 0 1
HYDRAULIC
Monocomponent 18 43-65 52.2 14 (77.7%) 0 8 (77.7%)
Ams-Hydroflex 10 47-55 50.5 8 0 8
Ams-Dynaflex 8 43-65 54 6 0 6
Multicomponents 120 26-85 58.4 25 (20.8%) 15 (12.5%) 36 (30%)
Mentor Alpha Ii 38 27-66 49.6 5 4 9
Ams 700 Cx 25 43-73 65.3 7 4 11
Coloplast Titan 20 26-74 45.4 4 3 6
Mentor Mark Ii 17 31-65 54.3 1 0 1
Ams700 Ultrex 14 41-85 62.8 8 3 9
Ams700 Lgx 3 66-71 63.3 0 0 0
Ams Ambicor 3 66-70 68 0 1 0
Table 2. 
500 penile prostheses implanted in relation with age of patients, mechanical failures, surgical complications 
and explanted cases with CKF on dialysis.
Pozza_Stesura Seveso  30/09/15  09:32  Pagina 218
219Archivio Italiano di Urologia e Andrologia 2015; 87, 3
500 penile prostheses implanted in Italy
surgery, which required 2 more days of hospitalization
and medical treatment.
In the first group of 50 hydraulic prostheses, implanted
without any drainage, 11 cases (22%) of scrotal
hematomas were recorded the day after surgery, requir-
ing longer observation and in 8 cases needle aspiration
and medical treatment. Since 2004 we routinely applied
scrotal drainage (16) observing only 5 cases (5.6%) of
scrotal hematoma due to obstruction of the drain. These
hematomas were easily evacuated using the tubing of the
draining system, prolonging hospitalization (to 3 and 4
days) in just two cases (2/5).
In one of these patients, who underwent AMS 700 CX
implantation after excision of a fibrous plaque of IPP and
Veritas patch (3x2 cm) insertion, we recorded an exten-
sive hematoma including the scrotum and penis. This
scrotal hematoma begun to appear soon after the defla-
tion of corporal cylinders the day after surgery, even with
an empty aspirating drainage. In this case we discovered
the hemorrhage after 3-4 hours. We re-inflated the cylin-
ders and after repeated aspiration succeeded in stopping
the hemorrhage. This patient developed an infection
some weeks later and after 2 months we decided to
remove the hydraulic system.
Micturition
Only 13 of 500 patients (0.26%) were unable to urinate
after removal of the urethral catheter the day after sur-
gery, thus requiring re-catheterization; this was main-
tained for the next day in 12 cases, while one patient was
discharged with the catheter still fitted. It was removed,
after medical treatment, 10 days post-surgery.
Infection
Fifteen (3%) cases of infections were recorded. Overall,
in 6 patients (1.2%) we had to explant the prosthesis
(19) (Table 2).
In 4 cases we observed high fever, chills and signs of
infections in the immediate period after surgery. In 3
cases, intravenous medical therapy resolved the infec-
tion. In one case the infection lasted more than 20 days
and we decided to explant the prosthesis.
In 2 cases (0.5%) of semi-rigid prosthesis and in 5 cases
(3.6%) of hydraulic prosthesis we recorded a prosthesis
infection after 3 to 18 months, requiring removal of the
prosthesis. Two patients (53 and 62 years, who suffered
from diabetes and hypertension) implanted respectively
with Mentor Mark II and AMS 700 CX started to devel-
op scrotal swelling with pain and skin perforation due to
extrusion of the scrotal pump after 45 days in the first
case and 36 days in the second. In both cases we
removed the prosthetic system entirely, leading to the
disappearance of infectious signs and symptoms. Both
patients refused a subsequent penile implant (20).
One patient (62 years, a smoker and hypertensive) start-
ed to develop fever and pain at the base of the penis 15
days post-surgery, and a small discharge of purulent yel-
lowish material began to appear from a small hole in the
skin at the base of the penis. The amount of purulent
material increased on squeezing the penis and inflating
the cavernous cylinders. The fistula was repeatedly
cleaned with iodopovidone and physiological solution
mixed with Gentamicin 3 times a day for 10 days, with
resolution of the discharge and ultimate closure of the
hole. After 8 years the patient continues to use his pros-
thesis satisfactorily.
Another “uncommon” infection arose in a 51-year-old
patient after replacement of a Mentor Alpha I due to tub-
ing leakage near the reservoir. After implantation of a
new Alpha I, the patient started to develop swelling of
the left hemiscrotum, with pain when touching the
pump. Fever was mild. The patient did not benefit from
a complex antibiotic therapy. The presence and persist-
ence of the inflammation and pain referred to the hemis-
crotum along with high white blood cells (WBC) counts
induced us to remove the hydraulic system after 20 days
of complex intravenous therapy, with an immediate drop
in fever and WBC counts and resumption of healing. The
patient did not wish to remain without a prosthesis. After
7 days without fever we therefore implanted two AMS
Spectra rods in order to keep the cavernous bodies open
until it was possible to implant another hydraulic system
(AMS 700CX), which was fitted in a different hospital 5
months later.
Mechanical problems
Apical extrusion of one prosthetic rod occurred in just 8
out of 362 semi-rigid (2.2%) prostheses. In 3 cases we cov-
ered the apical rupture and re-implanted a shorter semi-
rigid rod. In 5 cases the patients preferred to retain only
one rod, with satisfactory penetrative function (Table 2).
Three patients (0.8 %) with semi-rigid rods complained
of the “rotation” of the rods during sexual activity, with
some unpleasant discomfort.
We sometimes observed irregularity in the length of the
two cavernous bodies at the end of operation, in which
case we re-opened the cavernous body and extracted the
shorter rod in order to insert a longer Rear Tip extender
until obtaining good penile symmetry.
In 2 cases (1.4%) we had to re-operate due to incorrect
positioning and difficult activation of the pump into the
scrotum. Scrotal incision and re-positioning of the pump
were performed 5 and 25 days after the original opera-
tion and were uneventful. The prostheses continue to
work after 9 and 11 years.
We explanted 3 OmniPhase (1, 1 and 2 years after implan-
tation) and 2 DuraPhase (1 and 3 years after implantation)
prostheses due to breakage. Another patient decided to
maintain the broken rods without changing them.
We removed 14 (77.7%) of the 18 self-contained hydraulic
prostheses (8 Hydroflex and 6 Dynaflex) due to clearly evi-
dent malfunction 4-16 months post-surgery. The other 4
patients with self-contained prostheses were lost to follow-
up; they lived in different cities or in any case far from our
private clinic and in the event of any complications, prob-
ably consulted a different medical facility.
Leakage of the tubing with a completely non-functional
system occurred in 22 cases (15.9%) from 3 months to
96 months after implantation. Seventeen patients were
re-operated shortly thereafter (1-3 months), with
implantation of a new hydraulic prosthesis. Two of 5
patients who had discovered the malfunction after sever-
al months opted for fitting of a malleable prosthesis.
Three patients refused a new implant.
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In 3 cases of AMS700 Ultrex implantation there was a
malfunction due to aneurismatic dilatation of the cav-
ernous cylinders appearing 9, 10 and 16 months after
the implant. All 3 cases underwent explantation and sub-
sequent successful hydraulic prosthetic re-implantation.
In total we explanted 42/500 (8.4%) prostheses, of
which 6/362 (1.6%) malleable, 14/18 (77.7%) hydraulic
monocomponent and 22/120 (18.3%) hydraulic multi-
component.
Repeated prostheses
Three patients received 3 prostheses in the space of 5
years. All of them were first implanted with a Mentor
Acuform. After 3 years they wanted to switch to a
hydraulic multicomponent prosthesis. They received a
Mentor Alpha I (2 cases) and a AMS 700 cx (1 case). Two
patients suffered from subsequent infections and 1 from
tubing rupture, causing removal of the hydraulic system
in all cases. Finally, they were implanted with a semirigid
(Almed) prosthesis. 
Dissatisfaction, refusal
Thirty-two patients reported dissatisfaction with the
length of the operated penis (22).
In 8 cases, the patients’ disappointment was due to per-
ception of the tubing at the base of the penis.
Three patients reported absolute refusal with the pros-
theses. In 2 cases (one malleable and one hydraulic)
patients required subsequent explant (2 and 4 months
post-implant).
CONCLUSIONS
In our experience prosthetic implants appear to be a
good solution for erectile and penetrative dysfunction.
The surgical technique is relatively simple, even if some
problems can occur. Our data confirm that this kind of
surgery can be performed even in a small private clinic.
The possibility of having a penile prostheses under the
National Health System continues to be very difficult in
Italy. In several public hospitals, even with advanced
urological departments, there are no surgeons experi-
enced in penile prosthetic surgery and this solution is
not offered to patients with ED. Furthermore, many
General Practitioners do not consider a penile prosthesis
as a possible mean of restoring penetrative function. For
this reason, they do not normally suggest this solution to
any patients consulting them during the early phase of
the ED diagnostic process. The financial aspect of the
surgical treatment of ED may greatly limit the patient’s
choice if no other medical treatments are effective (23).
The number of patients submitted to PPI appears in line
with other distinguished European urological centers
(24, 25).
In our experience, younger patients preferred semi-rigid
silicone prostheses, considering them simpler to use dur-
ing sexual intercourse. Many of our younger patients
reported a subsidiary spontaneous erection of the tissue
surrounding the prosthetic rods during the preliminary
sexual phase (26). This “accessory” erection is also con-
sidered highly positive from an emotional point of view.
Many patients sometimes used 5PDEi to achieve better
subsidiary tumescence. The 6 patients aged over 80 years
did not experience any complications or problems differ-
ent to those in younger patients (27). They all confirmed
their satisfaction at the 1-year follow-up visit. In 1 case
with Coloplast Titan inflatable prosthesis a TURP for
BPH was easily performed.
Patient satisfaction with hydraulic prostheses was very
high (80%). The most important aspect is related to the
fact of having an erection only when sexual intercourse
is desired. Another reason is the possibility of having sex-
ual intercourse without informing their partner of its
presence, which can be easily masked.
Many of our patients reported that they did not tell their
partners about their prosthesis, even though we consider
the partner’s cooperation to be very important, especially
in the first sexual experiences following the penile
implant. Almost all our patients reported some relational
problems during the first months after PPI. It is extremely
important not to have to conceal the presence of the pros-
thesis and to practice pumping and deflating the cylinders.
In our experience a well-trained male can hide his pros-
thesis from a new partner for a considerable period.
More than 80% of partners who had been told about the
prosthesis declared their satisfaction with their partner’s
choice and no sexual refusal was reported to us.
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